Squarepoint’s Vera Therapeutics VERA Stock Holding History

Squarepoint’s Portfolio VERA Stock Details VERA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.5M	Buy	104,937 +89,253	+569%	+$3.33M	0.01%	1667
2026 Q1	$631K	Buy	+15,684	New	+$676K	﹤0.01%	3150
2025 Q3	–	Sell	-57,519	Closed	-$1.36M	–	5043
2025 Q2	$1.36M	Buy	57,519 +40,196	+232%	+$904K	﹤0.01%	2396
2025 Q1	$416K	Buy	+17,323	New	+$557K	﹤0.01%	3471
2024 Q4	–	Sell	-70,416	Closed	-$3.11M	–	5535
2024 Q3	$3.11M	Sell	70,416 -77,595	-52%	-$2.94M	﹤0.01%	1756
2024 Q2	$5.36M	Buy	148,011 +112,475	+317%	+$4.46M	0.01%	1326
2024 Q1	$1.53M	Buy	35,536 +17,148	+93%	+$611K	﹤0.01%	2278
2023 Q4	$283K	Buy	+18,388	New	+$234K	﹤0.01%	3402
2023 Q2	–	Sell	-66,116	Closed	-$513K	–	4047
2023 Q1	$513K	Buy	+66,116	New	+$510K	﹤0.01%	2286

Other funds holding VERA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Squarepoint's VERA Position: Q2 2026 in Review

Squarepoint increased its Vera Therapeutics (VERA) stake by 569% in Q2 2026, buying an estimated $3.33M and bringing the position to 104,937 shares worth $4.5M. The position accounts for 0.01% of the portfolio, ranked #1667.

Squarepoint first reported a position in VERA in Q1 2023 and has held it in 9 quarters since. The position peaked at $5.36M in Q2 2024. 220 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

Squarepoint held 104,937 shares of Vera Therapeutics worth $4.5M as of Q2 2026.
Squarepoint bought 89,253 Vera Therapeutics shares in Q2 2026, an estimated $3.33M.
Vera Therapeutics made up 0.01% of Squarepoint's portfolio in Q2 2026, its #1667 holding.
Squarepoint first reported a position in Vera Therapeutics in Q1 2023 and has held it in 9 quarters since.
Squarepoint's Vera Therapeutics position peaked at $5.36M in Q2 2024.
220 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.